Novo Nordisk A/s

Other

Xenia Pharma

Dorte Xenia Gram

Anker Jon Hansen

Jesper F Lau

Kristian Kjaergaard

Lars J Knutsen

Stefan Zahn

Soeren Lund

Louise Hjerrild Zeuthen

Malcolm Sheardown

Kristian Kjærgaard

Soren Lund

Kristian KJÆRGAARD

Søren Lund

The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

Anti-C5a receptor antibodies

The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

The present invention provides a method of treating diseases or disorders benefiting from inactivating or down-regulating the activity of the capsaicin receptor in a mammal by inhibiting the activity of the capsaicin receptor. The present invention also provides a method of treating obesity and obesity-related diseases and disorders in a mammal by inhibiting the activity of the capsaicin receptor.

Inhibition of the activity of the capsaicin receptor in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance or insulin resistance

The present invention provides a method of treating diseases or disorders benefiting from inactivating or down regulating the activity of the capsaicin receptor in a mammal by inhibiting the activity of the capsaicin receptor. The present invention also provides a method of treating obesity and obesity-related diseases and disorders in a mammal by inhibiting the activity of the capasaicin receptor.

Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders

The present invention relates to compounds of formula I ##STR1## wherein X is amino, C.sub.1-6 -alkylamino, di-C.sub.1-6 -alkylamino;

Treatment of ischemias by administration of 2,N.sup.6 -substituted

A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is halogen, trifluoromethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio, C.sub.1-6 -alkylamino or C.sub.1-6 -dialkylamino;

2, N.sup.6 -disubstituted adenosines, tri-O-ester derivatives and their

A method and a device for measuring the maturity of concrete, in which the heat generated by the setting of the concrete causes a special liquid to evaporate and the amount of evaporated liquid is taken as a measure of the concrete maturity. The liquid is contained in a closed capillary tube placed on a scale. For measuring purposes the capillary tube is broken at a well-defined point, and capillary and scale are then placed in a casing containing an absorbing agent for the evaporated liquid. The casing is hermetically sealed and pressed into the concrete. For reading purposes the casing is opened and the scale with the capillary is removed to determine the level of the liquid column and thus the maturity of the concrete.

Growing community of inventors

Charlottenlund, Denmark

Anker Jon Hansen